Holen Sie sich die Stockscreener-App
59.31
1.49%
-1.045
Schlusskurs vom Vortag:
$60.36
Offen:
$59.99
24-Stunden-Volumen:
314.77K
Relative Volume:
0.25
Marktkapitalisierung:
$8.83B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-946.53M
KGV:
-8.5144
EPS:
-6.9664
Netto-Cashflow:
$-814.94M
1W Leistung:
-3.44%
1M Leistung:
+2.39%
6M Leistung:
+0.24%
1J Leistung:
+81.72%
1-Tages-Spanne:
$59.05
$60.33
1-Wochen-Bereich:
$59.05
$62.14
52-Wochen-Spanne:
$30.81
$65.00
Vaxcyte Inc Stock (PCVX) Company Profile
Firmenname
Vaxcyte Inc
Sektor
Branche
Telefon
650-837-0111
Adresse
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
59.32 | 8.98B | 0 | -946.53M | -814.94M | -6.9664 |
VRTX
Vertex Pharmaceuticals Inc
|
522.57 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.98 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.41 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.62 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
208.90 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Bestätigt | Needham | Buy |
| 2025-09-12 | Eingeleitet | Goldman | Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-20 | Eingeleitet | Goldman | Buy |
| 2023-12-07 | Eingeleitet | Mizuho | Buy |
| 2023-04-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-03 | Bestätigt | Needham | Buy |
| 2022-12-15 | Eingeleitet | Guggenheim | Buy |
| 2022-11-17 | Eingeleitet | BTIG Research | Buy |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-06-24 | Fortgesetzt | Jefferies | Buy |
| 2020-07-07 | Eingeleitet | BofA Securities | Buy |
| 2020-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-07-07 | Eingeleitet | Needham | Buy |
Alle ansehen
Vaxcyte Inc Aktie (PCVX) Neueste Nachrichten
Why Are Vaxcyte (NASDAQ:PCVX) Shares Under Pressure After A Timeline Update? - Kalkine Media
Vaxcyte at Wells Fargo conference: broader vaccines, bigger stakes By Investing.com - Investing.com Canada
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing - The Globe and Mail
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know - The Motley Fool
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm - The Motley Fool
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm - The Motley Fool
Vaxcyte, Inc. (PCVX) Stock Analysis: Examining a Potential 78% Upside in the Biotech Frontier - DirectorsTalk Interviews
Vaxcyte (PCVX) Sets Phase 3 Pneumococcal Vaccine Data Release, M - GuruFocus
Vaxcyte narrows timing for pivotal VAX-31 data to late October (PCVX:NASDAQ) - Seeking Alpha
The Next Year Will Define Vaxcyte’s (PCVX) Vaccine Gamble - Yahoo Finance
Leadership Hires and OPUS-1 Timeline Could Be A Game Changer For Vaxcyte (PCVX) - simplywall.st
Vaxcyte Stock Price Forecast. Should You Buy PCVX? - StockInvest.us
Vaxcyte (NASDAQ: PCVX) officer plans new stock sale after recent trades - Stock Titan
Vaxcyte Inc. (PCVX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Vaxcyte stock jumps on new executives, VAX-31 data timeline - Investing.com
Vaxcyte Appoints New Chief Medical Officer, Updates Trial Timeline - TipRanks
Vaxcyte stock jumps on new executives, VAX-31 data timeline By Investing.com - Investing.com Nigeria
Vaxcyte Appoints Chief Medical Officer And Chief Legal Officer Narrows Guidance For Expected Vax-31 Opus-1 Topline Data - TradingView
Vaxcyte appoints two executives, narrows trial timeline By Investing.com - Investing.com Canada
Vaxcyte Inc (PCVX) Updates Phase 3 Trial Timeline, Market Pricin - GuruFocus
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data - Investing News Network
Vaxcyte appoints two executives, narrows trial timeline - Investing.com
Vaxcyte, Inc. Announces Management Changes - marketscreener.com
Vaxcyte COO Jim Wassil sells over $212,000 in company stock By Investing.com - Investing.com South Africa
Vaxcyte COO Jim Wassil sells over $212,000 in company stock - Investing.com
(PCVX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Vaxcyte Options Spot-On: On September 1st, 90,099 Contracts Were Traded, With 97,138 Open Interest - Moomoo
Vaxcyte (NASDAQ: PCVX) officer lines up new stock sale after recent trades - Stock Titan
Vaxcyte, Inc. (PCVX) Investor Outlook: Biotech Stock With An 82% Potential Upside - DirectorsTalk Interviews
Vaxcyte Inc. (PCVX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Vaxcyte Inc. (PCVX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Vaxcyte (PCVX) Pulls Back 2.2% to $59.84, Approaches Key Support at $56.85Volume Gap - vinanet.vn
Vaxcyte to Participate in Upcoming Investor Conferences - The Manila Times
Vaxcyte sets two online fireside chats for September dates - Stock Titan
Vaxcyte (PCVX) Q2 2026 Earnings: EPS Prints Above Forecast in the Latest Session; Investor Response: Shares Finish 1.13% Lower at the CloseProduct Revenue Analysis - vinanet.vn
Vaxcyte (PCVX) Earnings Snapshot: The Bottom-Line Figure Outpaces Its Comparison in Latest Trading; Session Move - vinanet.vn
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring a 74% Potential Upside in the Vaccine Innovation Leader - DirectorsTalk Interviews
Vaxcyte (PCVX) Earnings Snapshot: Profit Per Share Clears Its Benchmark in the Current Update; After Earnings: Shares Finish 2.09% Higher for the Current SessionEarnings Beat Alert - vinanet.vn
If You Followed Seth Klarman Into Vaxcyte in May, He Was Already Long Gone - AOL.com
Vaxcyte: Not Enough Safety Margin With Current Price (NASDAQ:PCVX) - Seeking Alpha
Vaxcyte (PCVX) Rallies 3.7% to $60.22 as Vaccine Pipeline Momentum BuildsBPI Bear Confirmed - vinanet.vn
PCVX Q2 2026 Earnings: Narrower-than-Expected Loss Yields 3.7% Share GainEPS Estimate Trend - vinanet.vn
Vaxcyte (PCVX) Climbs 3.14% to $59.90, Approaching Key Resistance at $62.90Breakaway Gap - vinanet.vn
Vaxcyte, Inc. (PCVX) Stock Analysis: Unraveling The 87.70% Potential Upside - DirectorsTalk Interviews
Seth Klarman Is Completely Out of Vaxcyte — Here's What's Left - Kavout | AI
Will Vaxcyte's (PCVX) Expanded Losses and Fully Enrolled VAX-31 Trials Reframe Its Risk‑Reward Narrative - simplywall.st
Finanzdaten der Vaxcyte Inc-Aktie (PCVX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Vaxcyte Inc-Aktie (PCVX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Wassil Jim | CHIEF OPERATING OFFICER |
Sep 01 '26 |
Option Exercise |
5.35 |
2,250 |
12,038 |
158,518 |
| Wassil Jim | CHIEF OPERATING OFFICER |
Sep 01 '26 |
Sale |
61.07 |
3,477 |
212,352 |
155,041 |
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):